Under the deal, which has already been approved unanimously by both companies’ boards, Sanofi will gain Kadmon’s drug Rezurock, which was approved in July to treat chronic graft-versus-host disease in both adults and adolescents.
Kadmon focuses on developing drugs for diseases with significant unmet medical needs.
“By leveraging Sanofi’s global resources and long-standing expertise in developing and commercializing innovative medicines, Rezurock is now well positioned for global accessibility, faster,” Harlan Waksal, MD, Kadmon’s president and CEO said in a news release.
Sanofi said it expects the deal to close in the fourth quarter of this year.
Read the full news release here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
